Journal: PLoS ONE

Article Title: Diagnostic performance and usability of the VISITECT CD4 semi-quantitative test for advanced HIV disease screening

doi: 10.1371/journal.pone.0230453

Figure Lengend Snippet: Characteristics of study participants in Phase 1.

Article Snippet: Developed by the Burnet Institute, the Omega VISITECT CD4 Advanced Disease Lateral Flow Assay (Visitect CD4 LFA) (Omega Diagnostics, Scotland, UK), is a disposable POC test that offers an estimation of the CD4 protein on the surface of CD4+ T cells, providing a semi-quantitative results at a threshold of 200cells/mm 3 [ ].

Techniques:

Journal: PLoS ONE

Article Title: Diagnostic performance and usability of the VISITECT CD4 semi-quantitative test for advanced HIV disease screening

doi: 10.1371/journal.pone.0230453

Figure Lengend Snippet: Contingency table of Visitect CD4 LFA test results with BD FACScount.

Article Snippet: Developed by the Burnet Institute, the Omega VISITECT CD4 Advanced Disease Lateral Flow Assay (Visitect CD4 LFA) (Omega Diagnostics, Scotland, UK), is a disposable POC test that offers an estimation of the CD4 protein on the surface of CD4+ T cells, providing a semi-quantitative results at a threshold of 200cells/mm 3 [ ].

Techniques:

Journal: PLoS ONE

Article Title: Diagnostic performance and usability of the VISITECT CD4 semi-quantitative test for advanced HIV disease screening

doi: 10.1371/journal.pone.0230453

Figure Lengend Snippet: Diagnostic performance of Visitect CD4 LFA at different CD4 cut-offs of the reference test.

Article Snippet: Developed by the Burnet Institute, the Omega VISITECT CD4 Advanced Disease Lateral Flow Assay (Visitect CD4 LFA) (Omega Diagnostics, Scotland, UK), is a disposable POC test that offers an estimation of the CD4 protein on the surface of CD4+ T cells, providing a semi-quantitative results at a threshold of 200cells/mm 3 [ ].

Techniques: Diagnostic Assay

Journal: PLoS ONE

Article Title: Diagnostic performance and usability of the VISITECT CD4 semi-quantitative test for advanced HIV disease screening

doi: 10.1371/journal.pone.0230453

Figure Lengend Snippet: Perception of the risk of operator-errors in the Visitect CD4 LFA testing workflow among testers.

Article Snippet: Developed by the Burnet Institute, the Omega VISITECT CD4 Advanced Disease Lateral Flow Assay (Visitect CD4 LFA) (Omega Diagnostics, Scotland, UK), is a disposable POC test that offers an estimation of the CD4 protein on the surface of CD4+ T cells, providing a semi-quantitative results at a threshold of 200cells/mm 3 [ ].

Techniques:

Journal: Medicina

Article Title: Point of Care Diagnostics for HIV in Resource Limited Settings: An Overview

doi: 10.3390/medicina54010003

Figure Lengend Snippet: Point of care CD4 technologies.

Article Snippet: Visitect CD4 (Omega Diagnostics, Alva, UK), a rapid disposable semi quantitative CD4 test, was launched in Washington D.C. at the 2012 AIDS conference and was developed by the Burnet Institute in collaboration with Omega Diagnostics Group.

Techniques: Flow Cytometry, Chromatography, Impedance Spectroscopy, Imaging, Cytometry, Immunostaining, Fluorescence

Journal: medRxiv

Article Title: High performance of CD4 rapid testing by lay providers in Malawi: Results from a prospective diagnostic accuracy study supporting decentralized advanced HIV disease screening

doi: 10.64898/2026.01.07.26343324

Figure Lengend Snippet: Figure 1 legend : CD4 counts by near point of care quantitative device performed by nurses (CD4 count on y axis) and by semiquantitative LFA by HIV diagnostic assistants (color of point). Horizontal lines indicate various CD4 cell counts. Light shaded dots show concordant results; discordant results are shown as dark shaded dots. Results for six participants with CD4 >1000 (all concordant) are not shown on graph.

Article Snippet: The semi-quantitative LFA used was VISITECT®CD4 test product (Accubio, UK) [11,14), the quantitative near point of care device-based test was the PIMA CD4 test machine (Abbott, USA).

Techniques: Diagnostic Assay